News & Analysis on Clinical Trial Services & Contract Research And Development
UPDATE
Beginning Sept. 30, Massachusetts-based CRO (contract research organization) Parexel will lay off as many as 125 of the 450 employees it brought on from GlaxoSmithKline (GSK) in North Carolina late last year, according to a North Carolina WARN report...
As the US regulator awards iclaprim expedited QIDP status, a former FDA antibiotics expert says the scheme boosts antibiotics without enough evidence for efficacy.
CDMO (contract development and manufacturing organization) Xcelience has made a structured cash investment in Pennsylvania-based Powdersize, which specializes in milling, micronization and powder size classification.
"People are the essence of the company going forward," said Teva, referring to the news that the world's largest generic drug maker will purchase Allergan's generics business for $40.5bn, at its Q2 financial results press conference on Thursday.
Late last month the China Food and Drug Administration (CFDA) began mandating that drug registration applicants self-inspect and verify clinical data to ensure that it’s authentic and reliable.
MannKind has announced it has opened two extra production lines for inhalable insulin powder Afrezza, its joint venture with Sanofi.
CRO Quintiles on Friday announced the pricing of a secondary public offering of 7,000,000 shares of its common stock at a price to the public of $77.85 per share, which is about $1 more per share than what the stock was selling for on Friday.